Please find the agenda for the conference below. Speaker details will be updated throughout the run up to the conference.

Our programme has been built around three key themes. To find out which sessions fall into each theme, please click register now where you will be able to view this in more detail.

  • Future scanning
  • Technology
  • Guidance and evidence 
08:00 - 09:00 Registration and refreshments
09:00 - 09:20 Welcome from the Chair of NICE
09:20 - 10:10

NICE futures
Over the last 20 years NICE has made a significant contribution to improving outcomes through its guidance standards and indicators, and been at the heart of the drive for evidence-based care, adoption ofinnovative practice and giving people a voice in the health and care system. The opening plenary assesses the impact of this contribution and discusses the role NICE should play as it enters its third decade.

Sir Andrew Dillon, Chief Executive, NICE​
Professor Lord Darzi of Denham, Chair, Accelerated Access Collaborative and Director, Institute of Global Health Innovation, Imperial College London
Eric Low, Senior Visiting Research Fellow, Leeds Institute of Clinical Trials Research and former CEO, Myeloma UK

10:10 - 10:50

Prevention or pills?
How should we balance investment in public health programmes with transformative medicines to ensure that we have a sustainable, effective health service?

Professor Yvonne Doyle, Regional Director London, Public Health England

10:50 - 11:30 Morning refreshments and networking  
11:30 - 12:25

Technology appraisals – fit for the future 

  • How NICE’s technology appraisals are responding to industry’s needs, including a discussion of managed access solutions and the new NICE commercial protocol, and NICE’s perspective on the Pharmaceutical Price Regulation Scheme.

Chair: Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE
Carla Deakin, Programme Director, Commercial & Managed Access, NICE 
Leslie Galloway, Chairman, Ethical Medicines Industry Group
Blake Dark, NHS Commercial Medicines Director, NHS England

Reliable evidence?: The roles of real-world data, patient evidence and randomised trials in judging treatment effectiveness

  • Randomised trials have been the gold standard for evidence of effectiveness, but increasing numbers of patients with multiple conditions and the growing sophistication of real-world data offer new perspectives on how to decide what works and for whom.

Professor Carl Heneghan, Director, Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford

Driving quality improvement in care

  • Evidence-based quality improvement delivers real change and improvement. Here’s how, with examples from NICE Scholars.

Chair: Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE
Dr Roshelle Ramkisson, NICE Scholar; Child and Adolescent Consultant Psychiatrist; Psychiatry Programme Director, North West, Health Education England

12:25 - 13:10

There’s an NHS approved app for that: the journey from digital concept to deployment

  • What evidence should manufacturers provide, what should evaluators and commissioners look for and how can NICE and innovators collaborate to get ideas deployed quickly and effectively?

Chair: Alexia Tonnel, Director of Evidence Resources, NICE
Neelam Patel, Chief Operating Officer, MedCity
Mark Salmon, Programme Director Information Resources, NICE
Dr Asma Khalil, Consultant Obstetrician, St George’s Hospital London and Member, Quality Standards Advisory Committees, NICE

Too much medicine? – is over-prescription harming patients?

  • Some clinicians, researchers, patients and policymakers believe overdiagnosis and overtreatment are harming patients. We discuss the controversies around concerns about inappropriate prescribing.

Paul Chrisp, Director, Centre for Guidelines, NICE
Imelda Redmond, National Director, Healthwatch England

NICE guidelines and standards for quality improvement: planning ahead for use in practice

  • Discover tools and resources from NICE to help you put our guidance into practice locally, learn how to keep your practice up to date with the latest evidence-based guidance and standards and understand how leaders at all level can drive change.

Speakers to be announced

13:10 - 14:15 Lunch   
13:30 - 14:00 Optional NICE Field Team drop in sessions  
14:15 - 15:10

The long term plan for life sciences: managing the innovation pipeline

  • The future of NICE healthtech assessments, how to identify innovations that the NHS needs and the latest developments and future role of HealthTech Connect.

Chair: Mirella Marlow, Programme Director Devices and Diagnostics Systems, NICE
Sheryl Warttig, Senior Technical Adviser, Centre for Health Technology Evaluation, NICE
Dr Sam Roberts, Director for Innovation and Life Sciences, NHS England
Kieran Murphy, Chair, Market Access Group, Association of British HealthTech Industries and Senior Director Market Access, Nevro

Bringing genomics to the clinical frontline

  • The NHS is the first health system to offer whole genome sequencing, to be delivered through seven Genomic Laboratory Hubs. We will discuss how genomics will transform NHS care, and how the system should prepare.

Professor John Mattick, Chief Executive, Genomics England
Sarah Byron, Assistant Director, Diagnostics Assessment Programme, NICE

Towards a learning health care system: accelerating the uptake of innovation and best practice – Dr Jennifer Dixon, Chief Executive, Health Foundation

In conversation with Richard Vize

Jennifer Dixon’s experience ranges from medical practice to policy analysis and research. Using this, plus the learning from the wide range of projects funded by The Health Foundation across the UK, she will be discussing the state of quality of health care at present, and how improvements might occur faster at the clinical front line.




15:10 - 15:50

Faster to Market

  • How industry can be more agile and timely in getting innovations to patients.

Chair: Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE
Professor Carole Longson, Chief Scientific Officer, Association of the British Pharmaceutical Industry
Michael Seres, Founder, 11Health
David Baghurst, General Manager, NIHR Office for Clinical Research Infrastructure (NOCRI) and director of research programmes, National Institute for Health Research

Session details to be confirmed

The aim of this session will focus on the challenges of mental health and care. Full session details will be released in due course once speaker confirmation have been received.

Beyond Brexit – UK medicines regulation, healthcare technology assessments and commissioning

  • As the UK departs the EU, what are the opportunities and challenges around a new approach to regulating assessing and commissioning technology?

Nick Crabb, Programme Director, Scientific Affairs, NICE
Patrick Carey, Deputy Director, EU and International Team, Medicines and Healthcare Products Regulatory Agency
Nina Pinwill, National Operational Lead, Cancer Drugs Fund, NHS England

15:50 - 16:20 Afternoon break and refreshments  
16:20 - 17:00

Closing plenary: Effectiveness and affordability: national and global futures
NICE’s work has stimulated global interest in using evidence to inform judgments about value for money and effectiveness. The final session looks at advances in this field in the UK, US and worldwide, discusses how the adoption of new technologies and practices is managed and reveals NICE’s transformational plans to develop and present its work through agile, interactive and adaptable guidance pathways.

Dr Steven Pearson, President, Institute for Clinical and Economic Review (ICER)
Professor Gill Leng, Deputy Chief Executive and Director of Health and Social Care, NICE
Dr Julian Treadwell, GP; In-Practice Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford